Cancer starts when a single cell accumulates enough genetic damage to ignore the body’s normal rules about when to grow, when to stop, and when to die. That one rogue cell divides into two, then four, then millions, eventually forming a mass of tissue called a tumor. About 1 in 5 people will develop cancer in their lifetime, with an estimated 20 million new cases diagnosed worldwide in 2022 alone. But the word “cancer” actually describes a complex, multi-step process that unfolds over years or even decades inside the body.
What Goes Wrong Inside a Cell
Your body contains trillions of cells, and each one follows a tightly controlled cycle of growth, division, and death. Two types of genes keep this cycle in check. The first type acts like a gas pedal, telling cells when it’s time to divide. The second type acts like a brake, stopping division when it’s not needed or when something has gone wrong. Cancer develops when mutations flip the gas pedal on permanently or knock out the brakes.
The gas-pedal genes, when mutated, are called oncogenes. In their normal form, they help regulate healthy cell growth. But when a mutation locks them into an “always on” position, cells keep dividing without receiving any signal to do so. The brake genes are called tumor suppressors, and they normally enforce checkpoints in the cell cycle, pausing division so the cell can repair damaged DNA or, if the damage is too severe, triggering the cell to self-destruct. When tumor suppressor genes are knocked out by mutations, those safety checkpoints disappear.
One of the most important tumor suppressors is a protein called p53, sometimes called “the guardian of the genome.” When DNA damage occurs in a healthy cell, p53 activates a cascade that either halts division to allow repairs or triggers a controlled self-destruction process called apoptosis. It does this by activating proteins that punch holes in the cell’s internal membranes, releasing signals that dismantle the cell from the inside. In roughly half of all human cancers, the gene encoding p53 is mutated and no longer functional. Without it, damaged cells survive and keep dividing, passing their broken DNA to every new generation of cells.
Why Mutations Happen
Every time a cell divides, it copies about 3 billion letters of DNA. Mistakes during this copying process are inevitable, and the body corrects most of them. But some slip through. Over a lifetime, these random errors accumulate. The vast majority of cancers arise from this kind of chance accumulation over time, combined with environmental exposures like tobacco smoke, ultraviolet radiation, certain chemicals, or chronic infections that increase the rate of DNA damage.
Only about 5 to 10 percent of cancers are caused by genetic mutations inherited from a parent. These inherited mutations give a person a head start toward cancer by knocking out one copy of a tumor suppressor gene in every cell from birth. It still takes additional mutations to trigger cancer, but the threshold is lower, which is why certain cancers run in families and tend to appear at younger ages.
How a Tumor Feeds Itself
A growing cluster of cancer cells quickly faces a problem: it needs oxygen and nutrients. No cell can survive more than a fraction of a millimeter from a blood vessel. To solve this, tumors hijack the body’s blood vessel construction system through a process called angiogenesis.
As cancer cells in the center of a growing mass become starved of oxygen, they switch on a stress-response signal that ramps up production of a protein that acts as a chemical beacon for nearby blood vessels. This signal reaches the cells lining existing blood vessels, prompting them to grow, divide, and sprout new branches directly toward the tumor. The result is a dedicated blood supply that delivers oxygen and nutrients straight to the cancer, fueling faster growth. This blood vessel recruitment is one of the key transitions that turns a small, harmless cluster of abnormal cells into a dangerous, rapidly expanding tumor.
How Cancer Hides From the Immune System
Your immune system is designed to recognize and destroy abnormal cells, and it catches and eliminates precancerous cells regularly. For a cancer to survive, it has to find a way around this surveillance. One of the most effective tricks cancer cells use involves exploiting the immune system’s own off switches.
T cells, the immune system’s primary cancer killers, have built-in “checkpoint” receptors on their surface that function like safety switches. These receptors exist to prevent the immune system from attacking the body’s own healthy tissue. Normally, when a T cell encounters a threat, it activates and destroys it. But when a molecule on a nearby cell binds to one of these checkpoint receptors, the T cell receives a “stand down” signal and goes dormant.
Cancer cells learn to exploit this system. Many tumors overload their surfaces with checkpoint-binding molecules, effectively holding up a fake ID that tells approaching T cells, “I’m a normal cell, move along.” The T cells that should be attacking the tumor instead become exhausted and inactive. This creates an immunosuppressive zone around the tumor where the immune response is effectively shut off. It’s not just the cancer cells that participate: surrounding support cells, immune cells recruited to the area, and even the structural tissue around the tumor can all begin displaying these same “stand down” signals, reinforcing the protective bubble.
How Cancer Spreads to Other Organs
Metastasis, the spread of cancer from its original site to distant organs, is responsible for the majority of cancer deaths. It’s a surprisingly complex journey that most cancer cells don’t survive.
To break free from a tumor, cancer cells undergo a transformation where they shed the sticky, anchored properties of their original tissue and take on a more mobile, fluid form. They lose the junctions that hold them to neighboring cells, reorganize their internal skeleton, and gain the ability to crawl through surrounding tissue. This shift allows them to burrow into nearby blood vessels or lymphatic channels and enter the bloodstream.
Traveling through the blood is dangerous for a cancer cell. The sheer force of circulation, attacks from immune cells, and the lack of a supportive environment mean that the vast majority of circulating cancer cells die. But a tiny fraction survives long enough to lodge in a distant organ, squeeze through the walls of a small blood vessel, and arrive in new tissue. Here, something remarkable happens: the cell reverses its transformation, shifting back to a more stationary form that can anchor itself and begin growing. This reversal appears to be critical for establishing a new tumor, which is why biopsies of metastatic tumors typically resemble the tissue of the original cancer rather than the organ they’ve invaded.
Common sites for metastasis include the lungs, liver, bones, and brain, though the pattern depends on the original cancer type. A tumor in the breast, for example, tends to spread to different organs than one in the colon.
The Hallmarks That Define All Cancers
Despite the hundreds of different cancer types, researchers have identified a set of core capabilities that virtually all cancers share. These are sometimes called the hallmarks of cancer, and the current framework, refined over two decades of research, includes eight functional capabilities along with several enabling conditions:
- Sustained growth signaling: cancer cells generate their own “grow” signals or amplify the ones they receive
- Evading growth suppressors: the braking mechanisms that stop normal cell division are disabled
- Resisting cell death: the self-destruct program (apoptosis) is blocked
- Unlimited replication: normal cells can only divide a fixed number of times before they age and stop; cancer cells bypass this limit
- Building blood vessels: tumors recruit their own blood supply through angiogenesis
- Invasion and metastasis: cancer cells gain the ability to move and colonize distant organs
- Reprogrammed metabolism: cancer cells rewire how they process energy, often favoring rapid, less efficient fuel burning that supports fast growth
- Immune evasion: tumors develop ways to avoid detection and destruction by the immune system
Underlying all of these is genome instability, the accelerating rate of mutations that gives cancer cells a constant supply of new genetic variations to draw from, along with chronic inflammation that can promote tumor development. More recently, researchers have proposed additional factors including the ability of cancer cells to shift their identity (cellular plasticity), changes in gene activity that don’t involve DNA mutations, and even the influence of the body’s microbial communities on tumor development.
How Staging Describes Severity
When cancer is diagnosed, one of the first things doctors determine is how far it has progressed. The most widely used system evaluates three factors: the size of the primary tumor (T), whether cancer has reached nearby lymph nodes (N), and whether it has spread to distant parts of the body (M). Each factor is assigned a number reflecting severity. A small, localized tumor with no lymph node involvement and no spread might be classified as T1, N0, M0, corresponding to early-stage disease. A large tumor that has reached multiple lymph nodes and spread to another organ would carry higher numbers across all three categories, indicating advanced disease. These combined scores translate into the familiar stage I through stage IV system, where higher stages reflect greater spread and typically more complex treatment.
How Modern Treatments Target Cancer
Traditional treatments like surgery, radiation, and chemotherapy work broadly: surgery removes the tumor physically, radiation damages the DNA of cancer cells in a specific area, and chemotherapy poisons rapidly dividing cells throughout the body (which is why it also affects hair follicles, gut lining, and other fast-growing healthy tissues). Newer approaches take a more precise aim.
Targeted therapies are drugs designed to attack specific molecules that cancer cells depend on. Small molecule inhibitors, for example, can slip inside cells and block the exact mutated protein driving a particular cancer’s growth. Because they’re tailored to a molecular target found primarily in cancer cells, they tend to cause less collateral damage than chemotherapy. One class blocks growth-signaling proteins, another interferes with the cell cycle machinery that cancer cells have hijacked, and others cut off the blood vessel signals that feed tumors.
Immunotherapy takes a different approach entirely. Rather than attacking cancer cells directly, it reactivates the immune system’s ability to recognize and destroy them. The most widely used immunotherapies are checkpoint inhibitors: drugs that block the “stand down” signals cancer cells use to disable T cells. By removing that fake ID, the treatment allows the immune system to see the tumor for what it is and mount an attack. Another form of immunotherapy uses lab-engineered antibodies that attach to specific proteins on cancer cell surfaces, flagging them for destruction by immune cells or delivering toxic payloads directly to the tumor.
These two strategies, targeted therapy and immunotherapy, are increasingly used together. Targeted drugs that kill cancer cells can release cellular debris that makes tumors more visible to the immune system, while immunotherapy can then sustain a longer-term immune response against any remaining cancer cells. This combination approach is reshaping treatment for cancers that were previously difficult to manage, including certain lung, skin, and kidney cancers.